Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab combo in pulmonary sarcomatoid carcinoma
NCT04725448Phase 2Unknown
- Sponsor
- Sichuan Cancer Hospital
- Start
- Apr 2021
- Primary completion
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in pulmonary sarcomatoid carcinoma (PSC), sponsored by Sichuan Cancer Hospital. Status: unknown.
02
Drugs
toripalimab
03
Conditions
pulmonary sarcomatoid carcinoma (PSC)
Beyond the preview
Go deeper on NCT04725448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04725448.